Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H11NO3.ClH |
| Molecular Weight | 217.649 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CNCC(=O)C1=CC=C(O)C(O)=C1
InChI
InChIKey=CSRRBDMYOUQTCO-UHFFFAOYSA-N
InChI=1S/C9H11NO3.ClH/c1-10-5-9(13)6-2-3-7(11)8(12)4-6;/h2-4,10-12H,5H2,1H3;1H
| Molecular Formula | C9H11NO3 |
| Molecular Weight | 181.1885 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Adrenalone is a keton form of the natural substrate epinephrine. Adrenalone is evidently formed in vivo by hydrolytic cleavage of the diester by esterases. It is an adrenergic receptor agonist. Adrenalone inhibits the norepinephrine synthesis and dopamine beta oxidase. It is known to have very weak sympathomimetic activity when compared to adrenaline. Adrenalone has the high radioprotective effect. It is a topical nasal decongestant. Adrenalone has hemostatic, sympathomimetic and vasoconstrictor therapeutic functions.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3102 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13899905 |
|||
Target ID: Norepinephrine synthesis Sources: https://www.ncbi.nlm.nih.gov/pubmed/13899911 |
|||
Target ID: CHEMBL2095203 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Stryphnon Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Radiation protective effect of beta-ketoanalogs of hydroxyphenyl ethanolamines]. | 1998-02-19 |
|
| Modified syntheses of dopamine-4-sulfate, epinephrine-3-sulfate, and norepinephrine-3-sulfate: determination of the position of the sulfate group by 1H-NMR spectroscopy. | 1988-08 |
|
| Analysis of USP epinephrine injections for potency, impurities, degradation products, and d-enantiomer by liquid chromatography, using ultraviolet and electrochemical detectors. | 1985-03-01 |
|
| Improved Delivery Through Biological Membranes. XVII. A Site-Specific Chemical Delivery System as a Short-Acting Mydriatic Agent. | 1984-07 |
|
| Formation of adrenaline in the iris-ciliary body from adrenalone diesters. | 1984-06 |
|
| Electron spin resonance-spin stabilization of semiquinones produced during oxidation of epinephrine and its analogues. | 1984-01-10 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9467647
Mice: 50-150 mumol/kg
Route of Administration:
Unknown
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21885739
Substrate uptake by norepinephrine transporter was reduced to 99% (27%) at 10-uM (100-uM) concentrations of adrenalone; the half maximal inhibitory concentration (IC50) value of adrenalone was 36.9 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:09:19 GMT 2025
by
admin
on
Mon Mar 31 18:09:19 GMT 2025
|
| Record UNII |
NN82YWE2IC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C87053
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
NN82YWE2IC
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | |||
|
66136
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | |||
|
200-525-7
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | |||
|
62-13-5
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | |||
|
SUB128139
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | |||
|
9407
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | |||
|
m1430
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID30211026
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | |||
|
C99565
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | |||
|
236364
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000153840
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY | |||
|
1011878
Created by
admin on Mon Mar 31 18:09:19 GMT 2025 , Edited by admin on Mon Mar 31 18:09:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|